Literature DB >> 27252040

The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.

Pier Luigi Zinzani1, Luigi Rigacci2, Maria Cristina Cox3, Liliana Devizzi4, Alberto Fabbri5, Francesco Zaja6, Alice Di Rocco7, Giuseppe Rossi8, Sergio Storti9, Pier Paolo Fattori10, Lisa Argnani1, Umberto Vitolo11.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27252040     DOI: 10.1080/10428194.2016.1184755

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  3 in total

1.  Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Authors:  Vittorio Stefoni; Cinzia Pellegrini; Alessandro Broccoli; Luca Baldini; Monica Tani; Emanuele Cencini; Amalia Figuera; Michela Ansuinelli; Elisa Bernocco; Maria Cantonetti; Maria Christina Cox; Filippo Ballerini; Chiara Rusconi; Carlo Visco; Luca Arcaini; Angelo Fama; Roberto Marasca; Stefano Volpetti; Alessia Castellino; Catello Califano; Marina Cavaliere; Guido Gini; Anna Marina Liberati; Gerardo Musuraca; Anna Lucania; Giuseppina Ricciuti; Lisa Argnani; Pier Luigi Zinzani
Journal:  Oncologist       Date:  2018-04-19

Review 2.  Targeting of epigenetic regulators in neuroblastoma.

Authors:  Luz Jubierre; Carlos Jiménez; Eric Rovira; Aroa Soriano; Constantino Sábado; Luis Gros; Anna Llort; Raquel Hladun; Josep Roma; Josep Sánchez de Toledo; Soledad Gallego; Miguel F Segura
Journal:  Exp Mol Med       Date:  2018-04-27       Impact factor: 8.718

3.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Authors:  Anna Dalla Pietà; Elisa Cappuzzello; Roberta Sommaggio; Antonio Rosato; Pierangela Palmerini; Annavera Ventura; Andrea Visentin; Giuseppe Astori; Katia Chieregato; Valentina Mozzo; Omar Perbellini; Maria Chiara Tisi; Livio Trentin; Carlo Visco; Marco Ruggeri
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.